Breaking News

Apotex Names President and CEO

August 27, 2014

Desai brings 30 years of pharma experience

Dr. Jeremy B. Desai has been appointed president and chief executive officer of Apotex replacing Jack Kay, who will serve as vice chairman of the board.
 
Dr. Desai has 30 years of pharmaceutical experience having held numerous senior positions. Dr. Desai has been with Apotex for the past 11 years, most recently serving as president and chief operating officer, and executive vice president and global head of R&D.
 
Apotex is among the largest Canadian pharmaceutical companies with more than 5,500 employees in Canada and 10,000 globally. It has exports to 75 countries with planned R&D expenditures of $2.1 billion within the next 10 years.
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.